Quick Answer
Definitive Healthcare Corp. reported Research And Development Expense of $34.78 million for the year ending 2025.
- Definitive Healthcare Corp. showed a decrease of -4.8% in Research And Development Expense from 2024 to 2025.
- This data is from Definitive Healthcare Corp.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $2.62 million | Q1 2021: $3.79 million | Q2 2021: $4.28 million | Q3 2021: $4.75 million | Q1 2022: $6.85 million | Q2 2022: $8.71 million | Q3 2022: $9.21 million | Q1 2023: $9.88 million | Q2 2023: $10.23 million | Q3 2023: $10.76 million | Q1 2024: $10.13 million | Q2 2024: $10.12 million | Q3 2024: $7.28 million | Q1 2025: $9.30 million | Q2 2025: $7.97 million | Q3 2025: $7.55 million.
- Over the full 6 years of available data (2020 to 2025), Definitive Healthcare Corp.'s Research And Development Expense has grown by 214.4%.
- Historical annual values: Fiscal year 2025: $34.78 million | Fiscal year 2024: $36.52 million | Fiscal year 2023: $42.44 million | Fiscal year 2022: $34.89 million | Fiscal year 2021: $18.57 million | Fiscal year 2020: $11.06 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: